Soluble lectin-like oxidized low density lipoprotein receptor-1 in type 2 diabetes mellitus

Tan, Kathryn Choon Beng; Shiu, Sammy W.M.; Wong, Ying; Leng, Lin; Bucala, Richard

doi:10.1194/jlr.m700551-jlr200

Cited by 67 publications

(72 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been shown that patients with metabolic syndrome are at high-risk of developing many disorders. The sLOX-1 levels have been shown to significantly increase in atherosclerotic plaque instability [23], diabetes mellitus [19], obesity [18], and are positively correlated with a reduction in body weight [24]. Association with coronary artery disease and metabolic disorders also suggested sLOX-1 as a biomarker for early detection of acute coronary syndrome [25,26].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble lectin-like oxidized low density lipoprotein receptor-1 in metabolic syndrome

2015

View full text Add to dashboard Cite

Background: Serum levels of soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) reflect increases in LOX-1 receptor expression associated with inflammation and metabolic disorders. Objectives: To examine sLOX-1 levels in metabolic syndrome and association of sLOX-1 with classical risk factors, and with metabolic syndrome, a clustering of metabolic disorders associated with cardiovascular risk factors. Methods: We selected 148 serum samples from patient participants with metabolic syndrome and 206 samples from patients with non-metabolic syndrome as controls, using the modified National Cholesterol Educational Program Adult Treatment Panel III (NCEP-ATP III) criteria. Results: Levels of sLOX-1 were increased significantly in participants with metabolic syndrome (P < 0.001). Serum sLOX-1 was positively associated with body mass index (BMI), blood pressure, fasting plasma glucose, triglyceride, and total cholesterol, but negatively associated with high-density lipoprotein cholesterol. Analysis of serum sLOX-1 for metabolic syndrome showed 99.03% specificity and 100% sensitivity. The area under the receiver operating characteristic curve was 0.998 (95%CI 0.996-1.001, P < 0.001). A univariate analysis showed sLOX-1 was significantly correlated with metabolic syndrome, but was not after adjustment for sex, age, blood pressure, and BMI. Multivariate regression analysis found that being overweight (82.3; 95%CI 10.7−631.9), hyperglycemia (1.1; 95%CI 1.1−1.2), and hypertriglyceridemia (1.1; 95%CI 1.0−1.1) were significantly correlated with metabolic syndrome. HDL cholesterol was a protective factor (0.96; 95%CI: 0.93−0.99). Conclusions: Serum sLOX-1 is a suitable biomarker for diagnosis of metabolic syndrome. However, univariate and multivariate analysis suggested that sLOX-1 may be a modulating factor, and not an independent risk factor.

show abstract

Section: Discussionmentioning

confidence: 99%

“…An elevated circulating level of sLOX-1 may reflect increases in LOX-1 receptor expression, inflammation, and metabolic disorder [15][16][17]. sLOX-1 is elevated in the plasma of individuals with obesity [18] and diabetic mellitus [19], which are characterized as medical conditions of metabolic syndrome.…”

mentioning

confidence: 99%

Soluble lectin-like oxidized low density lipoprotein receptor-1 in metabolic syndrome

2015

View full text Add to dashboard Cite

show abstract

“…Immunohistochemical analysis of diabetic rat aorta sections and human atherosclerotic plaques showed distinct elevated LOX-1 staining and provided evidence to suggest that LOX-1 expression is increased in the vasculature 29,30) . We have previously demonstrated that both LOX-1 and soluble LOX-1 expression in endothelial cell culture can be upregulated by AGEs in vitro 21) . Our current data suggest that mTOR is a critical signaling molecule involved in the upregulation of LOX-1 by AGEs, as the increase in LOX-1 is abolished by use of the mTOR inhibitor rapamycin.…”

Section: Discussionmentioning

confidence: 99%

“…LOX-1 is not constitutively expressed and the expression of LOX-1 can be induced by a number of stimuli including oxLDL 14,15) , shear stress 16) , inflammatory cytokines [17][18][19] and angiotensin Ⅱ 20) . We and other groups have shown that AGEs can also induce LOX-1 expression 17,21) . Since there is increased formation and accumulation of AGEs in diabetes mellitus, AGEs may contribute to the increased expression in LOX-1 seen in human diabetes 17,22) .…”

Section: Cell Culturementioning

confidence: 99%

Effect of Advanced Glycation End Products on Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 Expression in Endothelial Cells

Shiu

Wong

Tan

2012

JAT

Self Cite

View full text Add to dashboard Cite

“…Meanwhile, there is increasing evidence that increased LOX-1 expression is related to adipocyte metabolism and plays an important role in the development of metabolic disorders. Circulating sLOX-1 levels are signi cantly increased in obesity [11], in type 2 diabetes mellitus [12], and is correlated with body weight, BMI and total body fat [11]. In addition, Nomata et al recently reported that weight reduction can decrease circulating sLOX-1 levels in overweight middle-aged men [13].…”

mentioning

confidence: 99%

Serum sLOX-1 levels are associated with the presence and severity of angiographic coronary artery disease in patients with metabolic syndrome

Li¹,

Zhang²,

Yang³

et al. 2010

CIM

View full text Add to dashboard Cite

Serum sLOX-1 levels are associated with the presence and severity of angiographic coronary artery disease in patients with metabolic syndrome Abstract Purpose: Patients with metabolic syndrome are at high-risk for development of atherosclerosis and cardiovascular events. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1(sLOX-1) is associated with coronary artery disease (CAD) and metabolic disorders. We sought to assess whether serum sLOX-1 levels are correlated with the presence and severity of CAD in patients with metabolic syndrome (MetS) undergoing coronary angiography.Methods: Serum sLOX-1 levels were measured in 112 consecutive patients with MetS, undergoing coronary angiography for the evaluation of CAD. e severity of CAD was assessed by angiographic Gensini score system.Results: Serum sLOX-1 levels were signi cantly higher in MetS patients with CAD (n=69) than in those without CAD (n=43) (0.925 [range 0.137 to 1.432] ng/ml vs. 0.207 [range 0.063 to 0.774] ng/ml, P<0.01). Multivariate logistic regression analysis revealed that serum sLOX-1 level was independently associated with the presence of CAD (odds ratio 2.489, 95% con dence interval 1.290-4.802; P<0.01). Serum sLOX-1 levels were positively correlated with the Gensini score (ρ: 0.394, P<0.01) a er adjusting for other clinical characteristics.Conclusions: High sLOX-1 levels are associated with the presence and severity of CAD in patients with MetS. e measurement of serum sLOX-1may be potentially useful in predicting the presence and severity of CAD in patients with MetS. ORIGINAL RESEARCH © 2010 CIMClin In E398 Many epidemiological and clinical studies have con rmed the association between metabolic syndrome (MetS) and increased risk for coronary artery disease (CAD), which is the leading cause of mortality worldwide [1,2]. Morbidity and mortality from CAD are higher in patients with MetS [1]; therefore, early assessment of the risk of CAD in patients with MetS is desirable because it could lead to improved patient or physician adherence to risk-reducing behaviors or interventions and improve clinical outcomes. Lectin-like oxidized low-density lipoprotein receptor-1(LOX-1), a type II membrane glycoprotein, was initially identi ed as the major receptor for oxidized low-density lipoprotein (ox-LDL) in endothelial cells (ECs) and was later found also to have an inducible expression in macrophages and vascular smooth muscle cells (VSMCs) [3,4]. Like many cell-surface receptors with a single transmembrane domain, LOX-1 can be proteolytically cleaved at its membrane proximal extracellular domain and released as a soluble form (sLOX-1) [5]. e level of circulating sLOX-1 may re ect the expression of LOX-1 [6], and is increasing viewed as a biomarker for CAD. Circulating sLOX-1 levels are elevated in patients with acute coronary syndrome (ACS) [7] and are associated with in ammatory makers and oxidative stress markers in patients with CAD [8,9]. More recently, a prospective study has demonstrated that higher LOX index values are associated...

show abstract

Soluble lectin-like oxidized low density lipoprotein receptor-1 in type 2 diabetes mellitus

Cited by 67 publications

References 27 publications

Soluble lectin-like oxidized low density lipoprotein receptor-1 in metabolic syndrome

Soluble lectin-like oxidized low density lipoprotein receptor-1 in metabolic syndrome

Effect of Advanced Glycation End Products on Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 Expression in Endothelial Cells

Serum sLOX-1 levels are associated with the presence and severity of angiographic coronary artery disease in patients with metabolic syndrome

Contact Info

Product

Resources

About